Supreme Court nixes Abilify patent challenge; Can Bayer keep accelerating now that Eliquis is approved?;

@FiercePharma: Here's a novel job-preserving approach: U.K. politician urges NHS to use more of $AZN's Brilinta to stave off job cuts. More | Follow @FiercePharma

 @AlisonBFierce:Who gave you the flu? A new Facebook app helps you place the blame. Article | Follow @AlisonBFierce

> The U.S. Supreme Court turned away an appeal by generics maker Apotex, which had been challenging a patent on Abilify, the blockbuster antipsychotic marketed by Otsuka Pharmaceuticals and Bristol-Myers Squibb ($BMY). Report

> After an unusually strong 2012, can Bayer keep the ball rolling--especially now that Pfizer ($PFE) and Bristol-Myers Squibb have won approval for their Xarelto challenger Eliquis? Report

> The U.K.'s cost-effectiveness watchdog is opening up on preventive use of breast cancer drugs such as Tamoxifen. Report

> A U.K. politician urged the National Health Service to use more of AstraZeneca's ($AZN) blood thinner Brilinta as a way to keep the drugmaker's payroll from shrinking further. Report

> Indian pharma growth slowed during the quarter ended Dec. 31 for the first time in two years. Report

Medical Device News

 @FierceMedDev: ArthroCAD draws Series A for surgical device development. Story | Follow @FierceMedDev

@MarkHFierce: Given Imaging ended exploration of a possible sale or merger--for now, the PillCam maker will go it alone. More | Follow @MarkHFierce

 @DamianFierce: Covidien wants to see if its Hawk devices can work in combo PAD treatment, a potentially lucrative market. Report | Follow @DamianFierce

> Saliva gland could be secret to a Parkinson's disease Dx. Story

> St. Jude hit with FDA warning letter over Durata manufacturing. News

Biotech News

 @FierceBiotech: Roche picks Sanford-Burnham chief to revive lagging research group. Story | Follow @FierceBiotech

@JohnCFierce: Looks like Mene Pangalos, champion of virtual development, eliminating fixed costs, comes out on top of AZ R&D. Release | Follow @JohnCFierce

@RyanMFierce: Pharma's got blockbuster hopefuls on the move in 2013, but a special lack of Alzheimer's meds in the mix. More | Follow @RyanMFierce

> Versartis pockets $25M C round as it looks to PhII growth hormone study. Article

> Analysts pick the top blockbuster drug prospects in the class of '13. Report

> AstraZeneca research chief Mackay ousted in executive shakeup. News

Biotech Research News

> Stem cells cut heart damage in muscular dystrophy mice. News

> Targeting VEGF could do more harm than good in the eye. More

> Stem cells show early promise in ALS. Item

Pharma Manufacturing News

> Private equity firm lays out $212 million for API maker. News

> Spain's Idifarma sweats the small stuff. Story

> New manufacturing issues lead AbbVie to 2nd Synthroid recall. Article

> Stem cells show early promise in ALS. More

And Finally... Can high-tech gadgets improve your posture and perfect your golf swing? Report (sub. req.)


Suggested Articles

Esperion's Nexletol has had a rough road to approval after safety concerns nearly derailed its quest. But an FDA nod has the drug ready for market.

In an interview with Israel's Calcalist, Teva CEO Kåre Schultz shared details of his approach to the company's turnaround.

Nerlynx is already struggling in its extended adjuvant breast cancer setting, and new entrants from Daiichi-AZ and SeaGen could pressure it elsewhere.